DK2066669T3 - Adenosinderivater som A2A-receptoragonister - Google Patents
Adenosinderivater som A2A-receptoragonisterInfo
- Publication number
- DK2066669T3 DK2066669T3 DK07803477.4T DK07803477T DK2066669T3 DK 2066669 T3 DK2066669 T3 DK 2066669T3 DK 07803477 T DK07803477 T DK 07803477T DK 2066669 T3 DK2066669 T3 DK 2066669T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor agonists
- adenosine derivatives
- adenosine
- derivatives
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06120706A EP1903044A1 (en) | 2006-09-14 | 2006-09-14 | Adenosine Derivatives as A2A Receptor Agonists |
PCT/EP2007/059666 WO2008031875A1 (en) | 2006-09-14 | 2007-09-13 | Adenosine derivatives as a2a receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2066669T3 true DK2066669T3 (da) | 2011-01-10 |
Family
ID=37622170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07803477.4T DK2066669T3 (da) | 2006-09-14 | 2007-09-13 | Adenosinderivater som A2A-receptoragonister |
Country Status (31)
Country | Link |
---|---|
US (1) | US8188100B2 (da) |
EP (2) | EP1903044A1 (da) |
JP (1) | JP2010503639A (da) |
KR (1) | KR20090040386A (da) |
CN (1) | CN101511831B (da) |
AR (1) | AR062768A1 (da) |
AT (1) | ATE481404T1 (da) |
AU (1) | AU2007296227A1 (da) |
BR (1) | BRPI0716936A2 (da) |
CA (1) | CA2662104A1 (da) |
CL (1) | CL2007002658A1 (da) |
CR (1) | CR10621A (da) |
CY (1) | CY1110990T1 (da) |
DE (1) | DE602007009272D1 (da) |
DK (1) | DK2066669T3 (da) |
ES (1) | ES2353141T3 (da) |
HK (1) | HK1131392A1 (da) |
HR (1) | HRP20100694T1 (da) |
IL (1) | IL197153A0 (da) |
MA (1) | MA30722B1 (da) |
MX (1) | MX2009002811A (da) |
NO (1) | NO20091244L (da) |
PE (1) | PE20081151A1 (da) |
PL (1) | PL2066669T3 (da) |
PT (1) | PT2066669E (da) |
RU (1) | RU2009113668A (da) |
SI (1) | SI2066669T1 (da) |
TN (1) | TN2009000084A1 (da) |
TW (1) | TW200821324A (da) |
WO (1) | WO2008031875A1 (da) |
ZA (1) | ZA200901036B (da) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003029264A2 (en) * | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
PT2004654E (pt) | 2006-04-04 | 2013-08-27 | Univ California | Derivados de pirazolopirimidina para utilização como antagonistas da quinase |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
MY146645A (en) * | 2006-04-21 | 2012-09-14 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
BRPI0718792A2 (pt) * | 2006-11-10 | 2013-12-03 | Novartis Ag | Compostos orgânicos |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
AU2008313789A1 (en) * | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine AL receptor ligands |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MY159955A (en) | 2008-01-04 | 2017-02-15 | Intellikine Inc | Certain chemical entities, compositions and methods |
WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
KR20110039326A (ko) | 2008-07-08 | 2011-04-15 | 인텔리카인, 인크. | 키나제 억제제 및 사용 방법 |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
DK2358720T3 (da) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer med kondenseret ring |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
EP2678018A4 (en) | 2011-02-23 | 2015-09-30 | Intellikine Llc | COMBINATION OF CHINESE HEMMER AND USES THEREOF |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
UA121104C2 (uk) | 2013-10-04 | 2020-04-10 | Інфініті Фармасьютикалз, Інк. | Гетероциклічні сполуки і їх застосування |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
ES2913486T3 (es) | 2014-03-19 | 2022-06-02 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN105012318B (zh) * | 2014-04-17 | 2020-02-11 | 沈华浩 | 磺酰胺类化合物在气道慢性炎症性疾病中的应用 |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2018003058A (es) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas. |
CA3015847C (en) | 2016-03-16 | 2024-06-11 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
RU2748993C1 (ru) | 2017-09-28 | 2021-06-02 | СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. | Производное с конденсированным кольцом в качестве ингибитора рецептора a2a |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
US4738954A (en) | 1985-11-06 | 1988-04-19 | Warner-Lambert Company | Novel N6 -substituted-5'-oxidized adenosine analogs |
US4873360A (en) | 1986-07-10 | 1989-10-10 | Board Of Governors Of Wayne State University | Process for the preparation of cyclopentanoids and novel intermediates produced thereby |
US4954504A (en) | 1986-11-14 | 1990-09-04 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity |
EP0267878A1 (en) | 1986-11-14 | 1988-05-18 | Ciba-Geigy Ag | N9-cyclopentyl-substituted adenine derivatives |
JP2586897B2 (ja) | 1987-03-09 | 1997-03-05 | 富士薬品工業株式会社 | 光学活性なシス−シクロペンテン−3,5−ジオ−ルモノエステルの製造法 |
EP0550631B1 (en) | 1990-09-25 | 1997-01-02 | Rhone-Poulenc Rorer International (Holdings) Inc. | Compounds having antihypertensive and anti-ischemic properties |
IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
CA2241887C (en) | 1996-01-02 | 2004-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine |
US6376472B1 (en) | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
US6211165B1 (en) * | 1997-05-09 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
HUP0103025A3 (en) | 1998-06-23 | 2002-04-29 | Glaxo Group Ltd | A2a agonist 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives, medicaments containing the same, process for producing them and the useful intermediates |
GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
EP1121372B1 (en) | 1998-10-16 | 2006-06-28 | Pfizer Limited | Adenine derivatives |
ES2228163T3 (es) | 1998-12-31 | 2005-04-01 | Aventis Pharmaceuticals Inc. | Procedimiento para preparar derivados de desaza-adenosina n6-sustituidos. |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
EP1365776B1 (en) | 2001-01-16 | 2005-04-13 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
GB2372741A (en) | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,8-Disubstituted adenosine derivatives and their different uses |
US20040162422A1 (en) | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
EP1258247A1 (en) | 2001-05-14 | 2002-11-20 | Aventis Pharma Deutschland GmbH | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
ATE381336T1 (de) | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
EP1699459B1 (en) | 2003-12-29 | 2007-06-06 | Can-Fite Biopharma Ltd. | Method for treatment of multiple sclerosis |
JP2007526291A (ja) | 2004-03-05 | 2007-09-13 | ケンブリッジ・バイオテクノロジー・リミテッド | アデノシン受容体アゴニスト |
EP1746885A4 (en) | 2004-05-03 | 2010-09-08 | Univ Virginia | ADENOSINE A2A RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIC NEPHROPATHY |
AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
US7825102B2 (en) | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
PL1778239T3 (pl) | 2004-07-28 | 2014-01-31 | Can Fite Biopharma Ltd | Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena |
EP1794162A1 (en) | 2004-09-09 | 2007-06-13 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Purine derivatives as a3 and a1 adenosine receptor agonists |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
US20080051364A1 (en) | 2004-11-08 | 2008-02-28 | Pninna Fishman | Therapeutic Treatment of Accelerated Bone Resorption |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
JP5048520B2 (ja) | 2005-02-04 | 2012-10-17 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | E1活性化酵素の阻害剤 |
GB0505219D0 (en) | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
US20080300213A1 (en) | 2005-11-30 | 2008-12-04 | Pnina Fishman | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment |
EP1983990B1 (en) | 2006-01-26 | 2011-03-23 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | A3 adenosine receptor allosteric modulators |
EA031335B1 (ru) | 2006-02-02 | 2018-12-28 | Миллениум Фармасьютикалз, Инк. | Производные пирролопиримидинов |
WO2007092936A2 (en) | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
GB0607953D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607951D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
MY146645A (en) | 2006-04-21 | 2012-09-14 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
GB0607954D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607945D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
BRPI0718792A2 (pt) | 2006-11-10 | 2013-12-03 | Novartis Ag | Compostos orgânicos |
US20080312160A1 (en) | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
US20080262001A1 (en) | 2007-04-23 | 2008-10-23 | Adenosine Therapeutics, Llc | Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection |
US8153781B2 (en) | 2007-06-29 | 2012-04-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily |
US20090181934A1 (en) | 2007-10-17 | 2009-07-16 | Novartis Ag | Organic Compounds |
AU2008313789A1 (en) | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine AL receptor ligands |
US8183225B2 (en) | 2007-11-08 | 2012-05-22 | New York University | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists |
US20090181920A1 (en) | 2008-01-09 | 2009-07-16 | Pgxhealth, Llc | Intrathecal treatment of neuropathic pain with a2ar agonists |
-
2006
- 2006-09-14 EP EP06120706A patent/EP1903044A1/en not_active Ceased
-
2007
- 2007-09-12 AR ARP070104040A patent/AR062768A1/es not_active Application Discontinuation
- 2007-09-12 PE PE2007001224A patent/PE20081151A1/es not_active Application Discontinuation
- 2007-09-13 PL PL07803477T patent/PL2066669T3/pl unknown
- 2007-09-13 DK DK07803477.4T patent/DK2066669T3/da active
- 2007-09-13 BR BRPI0716936-1A2A patent/BRPI0716936A2/pt not_active IP Right Cessation
- 2007-09-13 CL CL200702658A patent/CL2007002658A1/es unknown
- 2007-09-13 AT AT07803477T patent/ATE481404T1/de active
- 2007-09-13 MX MX2009002811A patent/MX2009002811A/es not_active Application Discontinuation
- 2007-09-13 CN CN2007800333258A patent/CN101511831B/zh not_active Expired - Fee Related
- 2007-09-13 RU RU2009113668/04A patent/RU2009113668A/ru unknown
- 2007-09-13 ES ES07803477T patent/ES2353141T3/es active Active
- 2007-09-13 DE DE602007009272T patent/DE602007009272D1/de active Active
- 2007-09-13 WO PCT/EP2007/059666 patent/WO2008031875A1/en active Application Filing
- 2007-09-13 EP EP07803477A patent/EP2066669B1/en active Active
- 2007-09-13 US US12/310,254 patent/US8188100B2/en not_active Expired - Fee Related
- 2007-09-13 KR KR1020097005251A patent/KR20090040386A/ko active IP Right Grant
- 2007-09-13 CA CA002662104A patent/CA2662104A1/en not_active Abandoned
- 2007-09-13 PT PT07803477T patent/PT2066669E/pt unknown
- 2007-09-13 TW TW096134289A patent/TW200821324A/zh unknown
- 2007-09-13 SI SI200730448T patent/SI2066669T1/sl unknown
- 2007-09-13 AU AU2007296227A patent/AU2007296227A1/en not_active Abandoned
- 2007-09-13 JP JP2009527828A patent/JP2010503639A/ja not_active Withdrawn
-
2009
- 2009-02-13 ZA ZA200901036A patent/ZA200901036B/xx unknown
- 2009-02-19 IL IL197153A patent/IL197153A0/en unknown
- 2009-02-19 CR CR10621A patent/CR10621A/es not_active Application Discontinuation
- 2009-03-13 TN TN2009000084A patent/TN2009000084A1/fr unknown
- 2009-03-25 NO NO20091244A patent/NO20091244L/no not_active Application Discontinuation
- 2009-03-30 MA MA31736A patent/MA30722B1/fr unknown
- 2009-12-03 HK HK09111343.2A patent/HK1131392A1/xx unknown
-
2010
- 2010-12-14 HR HR20100694T patent/HRP20100694T1/hr unknown
- 2010-12-15 CY CY20101101154T patent/CY1110990T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2066669T3 (da) | Adenosinderivater som A2A-receptoragonister | |
DK2013211T3 (da) | Purinderivater til anvendelse som adenosin-A2A-receptoragonister | |
DK2018388T3 (da) | Bisadenosinforbindelser som adenosin A2A-receptoragonister | |
DK1841768T3 (da) | Purinderivater virkende som A2A-receptoragonister | |
DK2206710T3 (da) | Indolderivater som s1p1-receptor agonister | |
DK1863474T3 (da) | Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister | |
BRPI0817503A2 (pt) | Derivados de purina substituídos por pirimidina | |
DK1912991T3 (da) | Xanthinderivater som selektive HM74A-Agonister | |
DK2125792T3 (da) | Purinderivater som immunomodulatorer | |
DK2225231T3 (da) | Aminotriazolderivater som alx-agonister | |
DK1856110T3 (da) | Oxyindol derivater som 5HT4-receptor agonister | |
DK1989196T3 (da) | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister | |
ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten | |
ZA200810671B (en) | Purine derivatives as A2A agonists | |
DK2078001T3 (da) | Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer | |
ZA200902187B (en) | 8-Ethinylxanthine derivatives as selective A2A receptor antagonists | |
ATE486874T1 (de) | Purinonderivate als hm74a-agonisten | |
DK2007396T3 (da) | Enfumafungin-derivat som antimykotika | |
DE502007004416D1 (de) | Avermectinderivate |